Outcomes of Arterial Allografts Preserved at +2 to +8°C for Revascularization in Septic Settings

This study does not modify patient management or treatment. All patients undergoing treatment with an arterial allograft preserved at +2/+8°C as part of an arterial revascularization in a septic environment in either of the two centers between January 2024 and January 2025 will be included. Imaging exams and clinical follow-up data will be analyzed. Reinterventions and causes of death will be recorded. All imaging required for the 6-month follow-up is routinely performed as part of standard care. No modification of patient management is planned.

NCT Number	NCT06963255
Lead Sponsor	Hospices Civils de Lyon
Conditions	Revascularization in a Septic or Potentially Septic Environment
Enrollment	40 participants
Start Date	2024-06-03
Primary Completion	2025-12-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-08